Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience

Yıl: 2020 Cilt: 30 Sayı: 3 Sayfa Aralığı: 155 - 161 Metin Dili: İngilizce DOI: 10.4999/uhod.204238 İndeks Tarihi: 20-12-2020

Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience

Öz:
In patients with gastic cancer, five-year survival is poor in the locally advanced stage. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil(FLOT) combination regimen has been shown to provide a survival advantage in the locally advanced stage. In this study, weaimed to evaluate the efficacy and tolerability of FLOT with real-life data in patients with locally advanced gastric/esophagogastricjunction cancers. This retrospective study was conducted between June 2016 - March 2020 and included 106 patients’ data from sixcenters in Turkey. Median age was 60 (33-82). Primary tumor localization was stomach in 76 (71.7%) patients. Seventy-six (71.7%)patients were operated after median 4 (1-8 cycles) cycles of preoperative FLOT. Pathological complete regression (pCR)was obtainedin 10 (13.1%) of the operated patients. Median follow-up was 9.1 (1.4-45.7) months. One-year DFS was 63.2% and the two-yearOS was 65.1%. Three (2.8%) patients had chemotherapy-related deaths. Due to chemotherapy-related toxicity and intoleration, 19(17.9%) patients had dose reduction. The pCR obtained by FLOT appears higher than other regimens. This study is one of the raremulticentric real-life data showing the efficacy and tolerability of the FLOT regimen in the perioperative treatment in GC and EJC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin 68: 394-424, 2018.
  • 2. Smith DD; Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a Large US-Population Database. J Clin Oncol 23: 7114-7124, 2005.
  • 3. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22: 2069-2077, 2004.
  • 4. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340: 908-914 1999.
  • 5. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347: 995-999, 1996.
  • 6. Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the International Union Against Cancer classifi cation for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 3: 263-271, 2013.
  • 7. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol 40: 77-94, 2001.
  • 8. Gill S, Shah A, Le N, et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 21: 2070- 2076, 2003.
  • 9. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 25: 640-646, 2010.
  • 10. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218: 583-592, 1993.
  • 11. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
  • 12. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721, 2011.
  • 13. Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin,and capecitabine followed by resection in patients with oesophagealadenocarcinoma (UK MRC OE05): An open-label, randomised phase 3 trial. Lancet Oncol 18: 1249-1260, 2017.
  • 14. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17: 1697-708, 2016.
  • 15. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393: 1948-1957, 2019.
  • 16. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98: 1521-1530, 2003.
  • 17. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018).
  • 18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
  • 19. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28: 5210-5218, 2010.
  • 20. Starling N, Okines A, Cunningham D, et al. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer 100: 1725-1730, 2009.
  • 21. Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). Eur J Cancer 51 Suppl 3: 400, 2015.
APA YILDIZ F, ERASLAN E, Ilhan A, demir h, Demir N, erdur e, YILDIRIM O, Kanmaz H, ASLAN F, Tufan G, Durnalı A, OKSUZOGLU B, DEMIRCI U (2020). Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. , 155 - 161. 10.4999/uhod.204238
Chicago YILDIZ FATİH,ERASLAN EMRAH,Ilhan Aysegul,demir hacer,Demir Nazan,erdur erkan,YILDIRIM Ozgen Ahmet,Kanmaz Huseyin,ASLAN FERİT,Tufan Gülnihal,Durnalı Ayşe,OKSUZOGLU Berna,DEMIRCI UMUT Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. (2020): 155 - 161. 10.4999/uhod.204238
MLA YILDIZ FATİH,ERASLAN EMRAH,Ilhan Aysegul,demir hacer,Demir Nazan,erdur erkan,YILDIRIM Ozgen Ahmet,Kanmaz Huseyin,ASLAN FERİT,Tufan Gülnihal,Durnalı Ayşe,OKSUZOGLU Berna,DEMIRCI UMUT Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. , 2020, ss.155 - 161. 10.4999/uhod.204238
AMA YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. . 2020; 155 - 161. 10.4999/uhod.204238
Vancouver YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. . 2020; 155 - 161. 10.4999/uhod.204238
IEEE YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U "Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience." , ss.155 - 161, 2020. 10.4999/uhod.204238
ISNAD YILDIZ, FATİH vd. "Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience". (2020), 155-161. https://doi.org/10.4999/uhod.204238
APA YILDIZ F, ERASLAN E, Ilhan A, demir h, Demir N, erdur e, YILDIRIM O, Kanmaz H, ASLAN F, Tufan G, Durnalı A, OKSUZOGLU B, DEMIRCI U (2020). Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. Uluslararası Hematoloji-Onkoloji Dergisi, 30(3), 155 - 161. 10.4999/uhod.204238
Chicago YILDIZ FATİH,ERASLAN EMRAH,Ilhan Aysegul,demir hacer,Demir Nazan,erdur erkan,YILDIRIM Ozgen Ahmet,Kanmaz Huseyin,ASLAN FERİT,Tufan Gülnihal,Durnalı Ayşe,OKSUZOGLU Berna,DEMIRCI UMUT Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. Uluslararası Hematoloji-Onkoloji Dergisi 30, no.3 (2020): 155 - 161. 10.4999/uhod.204238
MLA YILDIZ FATİH,ERASLAN EMRAH,Ilhan Aysegul,demir hacer,Demir Nazan,erdur erkan,YILDIRIM Ozgen Ahmet,Kanmaz Huseyin,ASLAN FERİT,Tufan Gülnihal,Durnalı Ayşe,OKSUZOGLU Berna,DEMIRCI UMUT Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. Uluslararası Hematoloji-Onkoloji Dergisi, vol.30, no.3, 2020, ss.155 - 161. 10.4999/uhod.204238
AMA YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 155 - 161. 10.4999/uhod.204238
Vancouver YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 155 - 161. 10.4999/uhod.204238
IEEE YILDIZ F,ERASLAN E,Ilhan A,demir h,Demir N,erdur e,YILDIRIM O,Kanmaz H,ASLAN F,Tufan G,Durnalı A,OKSUZOGLU B,DEMIRCI U "Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience." Uluslararası Hematoloji-Onkoloji Dergisi, 30, ss.155 - 161, 2020. 10.4999/uhod.204238
ISNAD YILDIZ, FATİH vd. "Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience". Uluslararası Hematoloji-Onkoloji Dergisi 30/3 (2020), 155-161. https://doi.org/10.4999/uhod.204238